Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.
about
Relationship between radiation pneumonitis and organizing pneumonia after radiotherapy for breast cancerTranslational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma UniversityComplications from Stereotactic Body Radiotherapy for Lung CancerDosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma.Cyberknife: A double edged sword?Pulmonary toxicity in a rabbit model of stereotactic lung radiation therapy: efficacy of a radioprotector.Normal tissue toxicity after small field hypofractionated stereotactic body radiation.Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse modelToxicity risk of non-target organs at risk receiving low-dose radiation: case reportLow rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy.Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapyEffects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitisStereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects.Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates.Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case reportPneumomediastinum as a complication of SABR for lung metastasesVolumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapySBRT in operable early stage lung cancer patients.Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor.Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients.Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience.Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastases.Radiation dose-volume effects in the lung.Pentoxifylline Regulates Plasminogen Activator Inhibitor-1 Expression and Protein Kinase A Phosphorylation in Radiation-Induced Lung Fibrosis.Standardized Herbal Formula PM014 Inhibits Radiation-Induced Pulmonary Inflammation in Mice.Radiation pneumonitis after stereotactic radiation therapy for lung cancer.Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapyComparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy.Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms.Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution.Azithromycin attenuates acute radiation-induced lung injury in mice.A selenocysteine derivative therapy affects radiation-induced pneumonitis in the mouse.NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy.A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer.Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study.
P2860
Q21203114-B586C151-3EEE-41FF-AABB-461364AAB76DQ26744799-5D7D6A27-9FF6-446C-88FF-F424971928CBQ26995851-828A55FD-3C9F-4C97-A2E3-165E799395B6Q30401016-32C686B6-DAD5-4004-9498-08E03DEF11F7Q30445404-EDE20A30-9719-453B-8BBC-6F6F5DE35C95Q30458357-2714C10B-E443-40F8-80D7-6DBF20B12F0BQ30484881-85BB6C79-17CB-47AB-87AB-71BA57610D87Q33574341-29300D23-A3D9-4555-BA9D-E9370C5B1CC2Q33589860-2A166AFE-11BF-4F32-9EF9-36E1F7B6A565Q33805678-6FD01A33-4DB8-4209-9270-E46C536459E1Q33875793-A0CF7DFB-F607-41CC-A6F0-486C3B4E569AQ34277926-CE396F2A-A556-431A-BA6F-D417290854E4Q34304095-7CA66FB5-5C92-4D4E-8D71-C2F9E9695983Q34499545-53A7B153-E654-4AF8-BA86-047EF536B3DCQ34500185-8332359C-1C09-4030-8D7B-0BB5A0FEBDEEQ35036765-08CED45F-ABFF-4650-B867-A6FE366284CAQ35111353-F05F0A09-45C1-481F-8EBE-B50C6C31086AQ35200592-F0D526E8-863F-4AD9-88BF-B0974B23DB95Q36234741-0BDE2BD1-A2E2-46DE-9D74-383A1B7B0B70Q36502969-B6F6A2C2-9051-48A6-8A3D-3FA98935CB2AQ36524133-8C07FF1B-C072-4DD5-82CF-C07C661721B2Q36810626-685C142E-54BF-45F8-B245-42133D5D1800Q37450582-08D27D25-964F-4575-9A6F-19B262189D05Q37695563-8F7BA004-B231-4D6C-AE74-334C8A77DE73Q37699826-B3A0FBC2-CAF4-4342-8A7D-7A56802E316EQ37712927-19F1063C-0200-4DCC-B6E9-EEA1FDFB2122Q38256158-D2C2912A-D4B0-41B2-B9CD-7A8692A4FED9Q38757792-0E200382-53AB-4C59-8D7C-BEE628CD6FE2Q38871523-79268F70-25CC-4FB1-8AF4-D37A35EF7E0DQ39496906-4E6552F9-CE25-4019-99D8-F8C0E1A6926DQ41067520-80A8377B-90FB-4BD3-9EDA-CCD3BCFBFE1EQ41431618-AB8F9523-E69B-4435-BF5E-DEE578C5F572Q41887780-31EC7158-8E63-411E-B25A-0088A3D467D1Q42154657-97DBAD8D-D0F6-4FB9-8ED1-F175450520A9Q43196038-FC24A6AF-91CE-4AB5-941D-D60664F527D7Q45906084-B3390175-88FA-4898-B13E-61F3AA90C8FCQ46051924-3F3AF4BB-AA31-49C4-9A53-2F240D5DEA87Q46318727-9FCB0F29-A68F-4190-B817-64A4421C640DQ50695478-FD043C8E-6329-4B77-9F5D-5D4C63710C46Q51025454-F3F115B2-1DE0-46F1-9E0D-E513B91C0F4D
P2860
Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Exceptionally high incidence o ...... ation therapy for lung tumors.
@ast
Exceptionally high incidence o ...... ation therapy for lung tumors.
@en
type
label
Exceptionally high incidence o ...... ation therapy for lung tumors.
@ast
Exceptionally high incidence o ...... ation therapy for lung tumors.
@en
prefLabel
Exceptionally high incidence o ...... ation therapy for lung tumors.
@ast
Exceptionally high incidence o ...... ation therapy for lung tumors.
@en
P2093
P2860
P356
P1433
P1476
Exceptionally high incidence o ...... iation therapy for lung tumors
@en
P2093
Hideomi Yamashita
Hiroki Koyanagi
Keiichi Nakagawa
Kenshiro Shiraishi
Kuni Ohtomo
Masao Tago
Nakashi Sasano
Naoki Nakamura
P2860
P2888
P356
10.1186/1748-717X-2-21
P577
2007-06-07T00:00:00Z
P5875
P6179
1019069626